# Dihydroartemisinin for MAFLD

> **NCT07679542** · PHASE1,PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (estimated)

## Conditions studied

- MAFLD

## Interventions

- **DRUG:** Dihydroartemisinin

## Key facts

- **NCT ID:** NCT07679542
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-30
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07679542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07679542, "Dihydroartemisinin for MAFLD". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07679542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*